NCT06395662Completed
Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.
Improving the Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid. The ProBioRIS Study
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
Radiologically isolated syndrome (RIS) often precedes Multiple Sclerosis (MS) but some patients have no symptoms. This study aims to use biological samples and magnetic resonance imaging (MRI) data from four large cohorts of patients with MS in the United States, Europe and France, to stratify the chances of RIS developing into MS. Identifying early biomarkers to predict greater disease severity would have a significant impact, not only on RIS but also on the entire clinical spectrum of multiple sclerosis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 320 (actual)
- First submitted
- 29 Apr 2024
- Start date
- 15 Apr 2024
- Primary completion date
- 25 Jul 2025
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Diseases
- Multiple sclerosis
- NCT number
- NCT06395662
What you commit to
- Study type: Observational
- Participants enrolled: 320
- From 15 Apr 2024 to the primary completion date, 25 Jul 2025
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients with no biocollection, or with non-standardized magnetic resonance imaging acquisitions
Who the study is looking for
- Patients from the OFSEP, SFSEP, RISE and TERIS cohorts with centralized validated radiologoically isolated syndrome and a standardized magnetic resonance imaging from the OFSEP or Randomized Clinical Trials database.
- at least one cerebro-spinal fluid and/or serum sample at baseline available at a local or centralized biological resource center.
- if present, serum sample collected at the time of clinical conversion.
Sex: All
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| INTERNATIONAL CENTER OF RESEARCH IN INFECTIOLOGY, LYON UNIVERSITY, INSERM U1111, CNRS UMR 5308, ENS, UCBL 46 Allée d'Italie Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
| COTE D'AZUR UNIVERSITY, URRIS-UR2CA. Hôpital Pasteur 2, 30, Voie Romaine Coordinator of this site? Confirm its status | Nice | France | Unknown status |
| University of Texas, Southwestern Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.